About 50% of the complications of diabetes are the direct responsibility of hypertension (HT) [1], as in the case of kidney disease.

The relationship between diabetes and hypertension is very narrow: the presence of diabetes causes an increase in blood pressure, and hypertension is a risk factor for diabetes [1]. In this regard, Dr. Javier Salvador, Head, Department of Endocrinology and Nutrition, University Hospital of Navarra, stresses that "between 40 and 80% of diabetics have hypertension. However, if we tried to detect variations in blood pressure chronobiological possibly discover that the prevalence of abnormalities is higher. The frequent association of obesity and metabolic syndrome in type 2 diabetes itself facilitates the development of hypertension. "

The purpose of blood pressure control in diabetic patients is lower than in the nondiabetic population, and is set at odds of 130/80 mmHg [2], due to increased cardiovascular risk of these patients. Dr. Salvador considers that "there is still much room for improvement in this area": ​​although cross sections, measuring blood pressure "reaches at least 85% of patients, only 32% of people with type 2 diabetes show values ​​below 130/80 ".

If levels are altered, should be advised imposition of a change in lifestyle that includes healthy eating, exercise and systematic neglect of smoking, although it will be necessary to consider whether treatment can not be maintained levels within normal voltage.

Hypertension, responsible for the complications of diabetes
The endocrinologist considers that "both the blood pressure, and lipid profile and glycosylated hemoglobin values ​​are cornerstones to control in patients with diabetes" in order to reduce the development of micro and macrovascular complications and cardiovascular risk in general. And is that about 50% of the complications of diabetes are the direct responsibility of hypertension (HT) [1], including renal disease.

Dr. Salvador has stressed the importance of the kidneys in the treatment of patients with diabetes and has been referred to the art DPP4 inhibitors, which "represents an excellent alternative second step" for the treatment of diabetes because "do not produce hypoglycemia, its neutrality on body weight and easy to support combinations with other antidiabetic agents, including insulin."

Among iDPP4, the expert stressed due to the elimination of linagliptin biliary and fecal preferably "renal clearance is minimal, less than 5%, which can be used without dose adjustments in patients with any degree of renal impairment, in contrast with other DPP-4 inhibitors. "

Dr. Javier Salvador has moderated, with Dr. Jose Luis Llisterri, president of the Spanish Society of Primary Care Physicians (SEMERGEN), the plenary session "The new generation of iDPP4, why patient profiles are shown ", held as part of the 18th Annual Meeting of the Spanish Society of Hypertension - Spanish League for the Fight Against Hypertension. The session was conducted jointly by the SEH-LELHA, SEMERGEN and the Spanish Society of Endocrinology and Nutrition (SEEN), sponsored by the Boehringer Ingelheim and Lilly Partnership in Diabetes.

On diabetes
An estimated 371 million people suffer from diabetes type 1 and type 2 worldwide [3]. Type 2 diabetes is the most common type, and is estimated to represent 90% of all cases of diabetes [4]. Diabetes is a chronic disease that occurs when the body does not produce or properly use the hormone insulin [5].

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on four compounds representing developing several kinds of treatments. The partnership builds on the successes of both companies, which are two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record in innovation and research-based Lilly's innovative research, as well as his experience and history pioneered the field of diabetes. By joining forces, the companies demonstrate commitment to the care of patients with diabetes and are held together to focus on patient needs. Learn more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.

Boehringer Ingelheim "Value through Innovation"
The Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and has over 44,000 employees / as. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

A central element of the corporate culture, Boehringer Ingelheim is committed to socially responsible behavior. Therefore, the company is involved in social projects and takes care of its employees / as and families, offering equal opportunities to all. Respect, equal opportunity and the reconciliation of work and family life form the basis of mutual cooperation. Just as, environmental protection and sustainability are always present in any activity of Boehringer Ingelheim.

Boehringer Ingelheim was installed in Spain in 1952, and over the past 60 years has evolved to be in position # 10 of the pharmaceutical sector in our country. The company is based in Spain in Sant Cugat del Vallès (Barcelona), and currently has two international centers of production in Sant Cugat del Vallès and Malgrat de Mar. For more company information visit www.boehringer-Ingelheim. this is

About Lilly Diabetes
In its continued commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help health care professionals improve the lives of people with diabetes, and further research on innovative medicines to respond to the unmet needs of patients. For more information about Lilly's current products on diabetes visit www.lillydiabetes.es

About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of leaders in their field, applying the latest research in their laboratories around the world and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana (USA), Lilly provides answers-through medicines and information-for some of the most urgent medical needs of the world today. For more information visit www.lilly.es


1. Spanish Diabetes Society. Does it affect diabetes in my blood pressure?. Available

2. In the Sierra, Alejandro et.al. Evaluation and treatment of hypertension in Spain. Consensus document. Med Clin (Barc). 2008, 131 (3) :104-16

3. International Diabetes Federation. IDF Diabetes Atlas Poster. 2012 Update. 2012 (5th Edition).

4. World Health Organization: Fact Sheet No. 312 What is Diabetes? 2010

5. International Diabetes Federation. What is Diabetes?. IDF Diabetes Atlas. 2011 (5th Edition